| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Biology Research Laboratories, Takeda Chemical Industries, Ltd., Jusohonmachi, Yodogawa-ku, Osaka 532, Japan
Basic fibroblast growth factor (bFGF) is a potent angiogenic mitogen. To elucidate the effect of bFGF inhibitors in vivo, anti-bFGF immunoneutralizing monoclonal antibody was prepared. One monoclonal antibody against human bFGF, obtained by cell fusion and designated 3H3, completely inhibited bFGF-induced proliferation of human umbilical vein endothelial cells at a concentration of 100 ng/ml. 3H3 did not bind to acidic fibroblast growth factor or HST1 protein, indicating high specificity for bFGF. Furthermore, the immunoneutralizing activity of 3H3 was examined in vivo. K1000 cells (a BALB/c 3T3 transformant in which the leader sequence-fused bFGF gene was transfected) were transplanted s.c. into BALB/c nude mice. Growth of the tumor cells was inhibited by i.v. treatment with 3H3 at a concentration of 200 µg/mouse. Histological observation showed that the antitumor effect of 3H3 was due to the inhibition of bFGF-induced angiogenesis. This experiment provides direct causal evidence for the hypothesis that tumor growth is angiogenesis dependent. This finding could also have implications for the development of novel therapeutic approaches to angiogenic solid tumors.
1 To whom requests for reprints should be addressed, at Biology Research Laboratories, Takeda Chemical Industries, Ltd., Jusohonmachi, Yodogawa-ku, Osaka 532, Japan.
Received 5/22/91. Accepted 9/ 5/91.
This article has been cited by other articles:
|
|
 |
|
  N. Shimada, T. Ishii, T. Imada, K. Takaba, Y. Sasaki, K. Maruyama-Takahashi, Y. Maekawa-Tokuda, H. Kusaka, S. Akinaga, A. Tanaka, et al. A Neutralizing Anti-Fibroblast Growth Factor 8 Monoclonal Antibody Shows Potent Antitumor Activity against Androgen-Dependent Mouse Mammary Tumors In vivo Clin. Cancer Res., May 15, 2005; 11(10): 3897 - 3904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Meng, D. Tripathy, E. P. Frenkel, S. Shete, E. Z. Naftalis, J. F. Huth, P. D. Beitsch, M. Leitch, S. Hoover, D. Euhus, et al. Circulating Tumor Cells in Patients with Breast Cancer Dormancy Clin. Cancer Res., December 15, 2004; 10(24): 8152 - 8162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Aalinkeel, M. P. N. Nair, G. Sufrin, S. D. Mahajan, K. C. Chadha, R. P. Chawda, and S. A. Schwartz Gene Expression of Angiogenic Factors Correlates with Metastatic Potential of Prostate Cancer Cells Cancer Res., August 1, 2004; 64(15): 5311 - 5321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E.W. Cohen, M. W. Lingen, and E. E. Vokes The Expanding Role of Systemic Therapy in Head and Neck Cancer J. Clin. Oncol., May 1, 2004; 22(9): 1743 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Fernandez-Tornero, R. M. Lozano, M. Redondo-Horcajo, A. M. Gomez, J. C. Lopez, E. Quesada, C. Uriel, S. Valverde, P. Cuevas, A. Romero, et al. Leads for Development of New Naphthalenesulfonate Derivatives with Enhanced Antiangiogenic Activity: CRYSTAL STRUCTURE OF ACIDIC FIBROBLAST GROWTH FACTOR IN COMPLEX WITH 5-AMINO-2-NAPHTHALENESULFONATE J. Biol. Chem., June 6, 2003; 278(24): 21774 - 21781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Giavazzi, B. Sennino, D. Coltrini, A. Garofalo, R. Dossi, R. Ronca, M. P. M. Tosatti, and M. Presta Distinct Role of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor on Tumor Growth and Angiogenesis Am. J. Pathol., June 1, 2003; 162(6): 1913 - 1926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hagedorn, L. Zilberberg, J. Wilting, X. Canron, G. Carrabba, C. Giussani, M. Pluderi, L. Bello, and A. Bikfalvi Domain Swapping in a COOH-terminal Fragment of Platelet Factor 4 Generates Potent Angiogenesis Inhibitors Cancer Res., December 1, 2002; 62(23): 6884 - 6890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ruotsalainen, H. Joensuu, K. Mattson, and P. Salven High Pretreatment Serum Concentration of Basic Fibroblast Growth Factor Is a Predictor of Poor Prognosis in Small Cell Lung Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1492 - 1495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Klauber-DeMore, K. J. Van Zee, I. Linkov, P. I. Borgen, and W. L. Gerald Biological Behavior of Human Breast Cancer Micrometastases Clin. Cancer Res., August 1, 2001; 7(8): 2434 - 2439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Logothetis, K. K. Wu, L. D. Finn, D. Daliani, W. Figg, H. Ghaddar, and J. U. Gutterman Phase I Trial of the Angiogenesis Inhibitor TNP-470 for Progressive Androgen-independent Prostate Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1198 - 1203. [Abstract] [Full Text]
|
|
|
|
|
|
R. T.-P. Poon, S.-T. Fan, and J. Wong Clinical Implications of Circulating Angiogenic Factors in Cancer Patients J. Clin. Oncol., February 15, 2001; 19(4): 1207 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Giavazzi, R. Giuliani, D. Coltrini, M. R. Bani, C. Ferri, B. Sennino, M. P. M. Tosatti, A. Stoppacciaro, and M. Presta Modulation of Tumor Angiogenesis by Conditional Expression of Fibroblast Growth Factor-2 Affects Early but not Established Tumors Cancer Res., January 1, 2001; 61(1): 309 - 317. [Abstract] [Full Text]
|
|
|
|
|
|
A. Compagni, P. Wilgenbus, M.-A. Impagnatiello, M. Cotten, and G. Christofori Fibroblast Growth Factors Are Required for Efficient Tumor Angiogenesis Cancer Res., December 1, 2000; 60(24): 7163 - 7169. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Salven, A. Orpana, L. Teerenhovi, and H. Joensuu Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients Blood, December 1, 2000; 96(12): 3712 - 3718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Inoue, P. Perrotte, C. G. Wood, J. W. Slaton, P. Sweeney, and C. P. N. Dinney Gene Therapy of Human Bladder Cancer with Adenovirus-mediated Antisense Basic Fibroblast Growth Factor Clin. Cancer Res., November 1, 2000; 6(11): 4422 - 4431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Ke, Y.-X. Shi, S.-A. Im, X. Chen, and W. K. A. Yung The Relevance of Cell Proliferation, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor Production to Angiogenesis and Tumorigenicity in Human Glioma Cell Lines Clin. Cancer Res., June 1, 2000; 6(6): 2562 - 2572. [Abstract] [Full Text]
|
|
|
|
|
|
U. M. Gehling, S. Ergun, U. Schumacher, C. Wagener, K. Pantel, M. Otte, G. Schuch, P. Schafhausen, T. Mende, N. Kilic, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells Blood, May 15, 2000; 95(10): 3106 - 3112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Salven, L. Teerenhovi, and H. Joensuu A High Pretreatment Serum Basic Fibroblast Growth Factor Concentration Is an Independent Predictor of Poor Prognosis in Non-Hodgkin's Lymphoma Blood, November 15, 1999; 94(10): 3334 - 3339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Angelov, B. Salhia, L. Roncari, G. McMahon, and A. Guha Inhibition of Angiogenesis by Blocking Activation of the Vascular Endothelial Growth Factor Receptor 2 Leads to Decreased Growth of Neurogenic Sarcomas Cancer Res., November 1, 1999; 59(21): 5536 - 5541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Placido, C. Carlomagno, F. Ciardiello, M. D. Laurentiis, S. Pepe, A. Ruggiero, G. Tortora, L. Panico, A. D'Antonio, G. Pettinato, et al. Measurement of Neovascularization Is an Independent Prognosticator of Survival in Node-negative Breast Cancer Patients with Long-Term Follow-Up Clin. Cancer Res., October 1, 1999; 5(10): 2854 - 2859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Galy, A. Maret, A.-C. Prats, and H. Prats Cell Transformation Results in the Loss of the Density-dependent Translational Regulation of the Expression of Fibroblast Growth Factor 2 Isoforms Cancer Res., January 1, 1999; 59(1): 165 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M A Hull, J L Brough, D G Powe, G I Carter, D Jenkins, and C J Hawkey Expression of basic fibroblast growth factor in intact and ulcerated human gastric mucosa Gut, October 1, 1998; 43(4): 525 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Griscelli, H. Li, A. Bennaceur-Griscelli, J. Soria, P. Opolon, C. Soria, M. Perricaudet, P. Yeh, and H. Lu Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest PNAS, May 26, 1998; 95(11): 6367 - 6372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Cao, A. Chen, S. S. A. An, R.-W. Ji, D. Davidson, Y. Cao, and M. Llinas Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth J. Biol. Chem., September 5, 1997; 272(36): 22924 - 22928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bastaki, E. E. Nelli, P. Dell'Era, M. Rusnati, M. P. Molinari-Tosatti, S. Parolini, R. Auerbach, L. P. Ruco, L. Possati, and M. Presta Basic Fibroblast Growth Factor–Induced Angiogenic Phenotype in Mouse Endothelium : A Study of Aortic and Microvascular Endothelial Cell Lines Arterioscler. Thromb. Vasc. Biol., March 1, 1997; 17(3): 454 - 464. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. R. Dover and A. W. Valley Review : Angiogenesis: A new target for antineoplastic therapy Journal of Oncology Pharmacy Practice, January 1, 1996; 2(1): 43 - 60. [Abstract] [PDF]
|
|
|
|
 |
|
 R Hoffman, D. Paper, J Donaldson, S Alban, and G Franz Characterisation of a laminarin sulphate which inhibits basic fibroblast growth factor binding and endothelial cell proliferation J. Cell Sci., January 11, 1995; 108(11): 3591 - 3598. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
